These data demonstrate that SB203580 exhibited a therapeutic effect on ESCC by blocking RPS15 via the p38 MAPK pathway with the effect being augmented by the combination treatment with DDP. The gene discussed is RPS15; the disease is esophageal squamous cell carcinoma.